Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.

BACKGROUND Changes within the gut microbiota contribute to the progression of chronic liver diseases. According to the results of several studies performed in animal models, gut dysbiosis plays an important role in hepatocarcinogenesis. The aim of this study was to explore the characteristics of gut microbiota associated with the presence of hepatocellular cancer (HCC) in patients with cirrhosis of the liver undergoing liver transplantation. METHODS A total of 15 patients with HCC and 15 non-HCC patients matched according to etiology of cirrhosis and Model for End-Stage Liver Disease (MELD) scores who underwent liver transplantations between 2012 and 2014 were included. Analysis of their gut microbial profile was based on prospectively collected stool samples from the pretransplant period. RESULTS Patients with and without HCC were similar with respect to age (P = .506), sex (P = .700), hepatitis C virus (P > .999) and hepatitis B virus (P = .715) infection status, alcoholic liver disease (P > .999), and MELD score (P = .337). Notably, the presence of HCC was associated with significantly increased fecal counts of Escherichia coli (P = .025). Prediction of HCC presence based on E coli counts was associated with the area under the receiver-operating curve of 0.742 (95% confidence interval, 0.564-0.920), with the optimal cutoff on the level of 17.728 (natural logarithm of colony-forming units per 1 g of feces). Sensitivity and specificity rates for the established cutoff were 66.7% and 73.3%, respectively. CONCLUSIONS The profile of gut microbiota associated with the presence of HCC in cirrhotic patients is characterized by increased fecal counts of E coli. Therefore, intestinal overgrowth of E coli may contribute to the process of hepatocarcinogenesis.

[1]  Aijaz Ahmed,et al.  Diabetes Mellitus, and Not Obesity, Is Associated with Lower Survival Following Liver Transplantation , 2015, Digestive Diseases and Sciences.

[2]  M. Krawczyk,et al.  The relevance of intestinal dysbiosis in liver transplant candidates , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  M. Karin,et al.  Inflammation and liver tumorigenesis , 2013, Frontiers of Medicine.

[4]  Hongyang Wang,et al.  Multiple interactive factors in hepatocarcinogenesis. , 2014, Cancer letters.

[5]  B. Chassaing,et al.  Microbiota‐liver axis in hepatic disease , 2014, Hepatology.

[6]  K. McGlynn,et al.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.

[7]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[8]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[9]  K. Zieniewicz,et al.  Combination of Morphologic Criteria and α-Fetoprotein in Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation Minimizes the Problem of Posttransplant Tumor Recurrence , 2014, World Journal of Surgery.

[10]  P. Hylemon,et al.  Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy , 2015, Hepatology.

[11]  S R Tannenbaum,et al.  Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens , 2009, Gut.

[12]  L. Tang,et al.  Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. , 2012, Journal of hepatology.

[13]  G. Esmat,et al.  Role of Helicobacter pylori in patients with HCV‐related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression , 2012, Journal of viral hepatitis.

[14]  C. Sonnenday,et al.  Predictors of Early Hospitalization After Deceased Donor Liver Transplantation , 2015, Digestive Diseases and Sciences.

[15]  D. Pezet,et al.  Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. , 2014, World journal of gastroenterology.

[16]  B. Sharma,et al.  A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy , 2011, European journal of gastroenterology & hepatology.

[17]  M. Krawczyk,et al.  Gut microbiota in cirrhotic liver transplant candidates. , 2014, Hepato-gastroenterology.

[18]  Emmanuel Buc,et al.  Colonization of the Human Gut by E. coli and Colorectal Cancer Risk , 2013, Clinical Cancer Research.

[19]  Y. Chawla,et al.  Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. , 2014, Gastroenterology.

[20]  M. Merli,et al.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. , 2014, World journal of gastroenterology.

[21]  M. Krawczyk,et al.  Effects of Donor Age and Cold Ischemia on Liver Transplantation Outcomes According to the Severity of Recipient Status , 2015, Digestive Diseases and Sciences.

[22]  Long-term results of liver resection in the treatment of patients with hepatocellular carcinoma. , 2011, Polski przeglad chirurgiczny.

[23]  R. Stravitz,et al.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis , 2014, Alimentary pharmacology & therapeutics.

[24]  D. Brenner,et al.  Role of Gut Microbiota in Liver Disease. , 2015, Journal of clinical gastroenterology.

[25]  Masahira Hattori,et al.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.

[26]  D. Pezet,et al.  High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon Cancer , 2013, PloS one.

[27]  N. Shinomiya,et al.  Helicobacter pylori Augments Growth of Gastric Cancers via the Lipopolysaccharide-Toll-like Receptor 4 Pathway whereas Its Lipopolysaccharide Attenuates Antitumor Activities of Human Mononuclear Cells , 2008, Clinical Cancer Research.

[28]  P. Gow,et al.  Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed , 2016, Hepatology.

[29]  Giuseppe Realdi,et al.  Helicobacter Infection in Patients with HCV-Related Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma , 2002, Digestive Diseases and Sciences.

[30]  M. Minemura,et al.  Gut microbiota and liver diseases. , 2015, World journal of gastroenterology.